Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last SFr.112.80 CHF
Change Today +0.20 / 0.18%
Volume 135.4K
ATLN On Other Exchanges
SIX Swiss Ex
As of 6:42 AM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

actelion ltd-reg (ATLN) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/15/15 - SFr.125.10
52 Week Low
04/14/14 - SFr.79.46
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ACTELION LTD-REG (ATLN)

Related News

No related news articles were found.

actelion ltd-reg (ATLN) Related Businessweek News

No Related Businessweek News Found

actelion ltd-reg (ATLN) Details

Actelion Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for diseases with unmet medical needs. It offers Tracleer, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH), a chronic and life-threatening disorder that severely compromises the functions of the lungs and heart; and Opsumit, an orally available endothelin receptor antagonist for the treatment of PAH to delay disease progression. The company also provides Veletri, an intravenous prostacyclin for the treatment of PAH to enhance exercise capacity; and Ventavis, an inhaled synthetic analog of prostacyclin for the treatment of PAH to enhance a composite endpoint consisting of exercise tolerance, symptoms, and lack of deterioration. In addition, it offers Valchlor, a chemotherapeutic agent for the treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients; and Zavesca, an oral treatment for patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable. Actelion Ltd markets its products in Switzerland, the United States, Europe, Japan, China, Russia, Mexico, and internationally. The company was founded in 1997 and is headquartered in Allschwil, Switzerland.

Founded in 1997

actelion ltd-reg (ATLN) Top Compensated Officers

Founder, Chief Executive Officer, Member of M...
Total Annual Compensation: SFr.2.7M
Compensation as of Fiscal Year 2014.

actelion ltd-reg (ATLN) Key Developments

Actelion Ltd. Announces Outcome Data from Phase III PAH Study

Actelion Ltd. announced long-term outcome data from the selexipag Phase III GRIPHON study in patients with pulmonary arterial hypertension, or PAH. The presentation highlighted that the investigational drug selexipag significantly reduced the risk of a morbidity/mortality event by 40% versus placebo (p5%) on selexipag compared to placebo, over the course of the study, were headache, diarrhea, jaw pain, nausea, myalgia, vomiting, pain in extremity, and flushing. Over the course of the study, the proportion of patients discontinuing treatment due to adverse events, without a morbidity or mortality event, was 14% on selexipag and 7% on placebo.

Actelion Ltd. - Shareholder/Analyst Call

To present effect of selexipag on morbidity/mortality in pulmonary arterial hypertension: results of the GRIPHON study

Actelion Ltd. Announces Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015

Actelion Ltd. announced earnings results for the fourth quarter and full year ended December 31, 2014. For the year, the company reported core earnings of CHF 743 million, up 25% at CER. Core EPS was CHF 5.58, an increase of 33% at CER. The company reported product sales was CHF 1,956 million against CHF 1,784 million for the same period a year ago. Core net income was CHF 648 million or CHF 5.58 per diluted share against CHF 509 million or CHF 4.41 per diluted share for the same period a year ago. Fully diluted earnings per share increased to CHF 5.11, the higher share price resulted in an increased share count despite a decreased nominal number of outstanding equity instruments. It reported net income of CHF 594 million, boosted by an income tax benefit. Net income for the year ended December 31, 2014 was CHF 593.8 million or CHF 5.11 per diluted share, compared to CHF 452.54 million, or CHF 3.92 per diluted share, for the year ended December 31, 2013. For the fourth quarter, the company reported product sales of CHF 468.23 million against CHF 462.15 million for the same period a year ago. Core earnings were CHF 113 million against CHF 124 million for the same period a year ago. Core net income was CHF 94 million or CHF 0.81 per diluted share against CHF 102 million or CHF 0.87 per diluted share for the same period a year ago. Net income for the fourth quarter ended December 31, 2014 was CHF 27.79 million, or CHF 0.24 per diluted share, compared to CHF 148.06 million, or CHF 1.27 per diluted share, for the same quarter ended December 31, 2013. For the year 2015, the company expects low-single core earnings growth at CER. For 2015, the company is not expecting such material deferred tax benefits as in 2014. And therefore, it expects the effective tax rate to remain in a similar range, around 11%, both for core and U.S. GAAP results. The company expects 2015 core earnings to grow in the low single-digit percentage range.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATLN:VX SFr.112.80 CHF +0.20

ATLN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ipsen SA €44.55 EUR +0.54
Meda AB kr139.80 SEK +3.30
Recordati SpA €17.53 EUR +0.13
UCB SA €67.70 EUR +0.35
United Therapeutics Corp $172.44 USD -4.37
View Industry Companies

Industry Analysis


Industry Average

Valuation ATLN Industry Range
Price/Earnings 23.1x
Price/Sales 6.7x
Price/Book 6.8x
Price/Cash Flow 20.5x
TEV/Sales 6.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTELION LTD-REG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at